Nymox Reports Third Quarter 2009 Financial Results

Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the third quarter of 2009. Nymox reported a net loss of $1,362,840, or $0.04 per share for the quarter and $3,587,251, or $0.12 per share for the nine months ending September 30, 2009, compared to $1,318,293, or $0.04 per share for the quarter and $3,714,188, or $0.13 per share for the nine months ending September 30, 2008. Net losses include stock compensation charges for the quarter of $322,808 in 2009 and $293,180 in 2008 and for the nine months of $881,344 in 2009 and $702,540 in 2008. The increase of the net loss for the quarter is mainly attributable to expenses relating to the launch of Phase 3 clinical trials for NX-1207. The decrease in net losses for the nine months period is attributable to reduced general and administrative expenditures compared to 2008. Product sales amounted to $71,904 for the quarter and $248,471 for the nine months ending September 30, 2009, compared to $82,171 and $306,849 for the same periods in 2008 due to a decrease in sales attributable to the current economic slowdown. The weighted average number of common shares outstanding for the nine months ended September 30, 2009 was 30,570,732 compared to 29,646,249 for the same period in 2008.

Nymox Pharmaceutical Corporation is a biotechnology company engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. The Company's new drug for benign prostatic hyperplasia (BPH) is in Phase 3 development. Currently Nymox has three products on the market, and a healthy pipeline of drug and diagnostic products. The Company also has several hundred patents and patent applications. Nymox has a number of drugs in development for other indications such as E. coli infection, Alzheimer's disease, oncology, and infectious disease. The Company offers NicAlert(TM) and TobacAlert(TM) tests for measuring tobacco product exposure, and AlzheimAlert(TM), a test to aid in the diagnosis of Alzheimer's disease.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Nymox Pharmaceutical Corporation

CONTACT:  Nymox Pharmaceutical Corporation
Roy Wolvin
1-800-93NYMOX
www.nymox.com

Related terms: alzheimers, biotechnology, clinical, disease, drugs, email, financial results, infection, nasdaq, patent, pharmaceuticals, pipeline, population, products, sales, securities, tobacco